Full index of posts »
Cytokinetics: New Collaboration With Astellas On CK-2127107 Greatly Improves Investment Outlook http://seekingalpha.com/p/24u9p Dec 24, 2014
Neuralstem: Some Encouraging, But Very Early, Information On Chinese Ischemic Stroke Trial Using NSI-566... http://seekingalpha.com/p/24hf7 Dec 18, 2014
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct $NWBO http://seekingalpha.com/a/1mb2j Dec 1, 2014
- mike711 on Neuralstem: A Closer Look At Encouraging Phase 2 Results For NSI-566 Neural Stem Cells In Treating ALS (CUR, Buy, $2.36) Mr. Smith please comment on my thought concerni...
- sfrue on Comments On Data Presented By Northwest Biotherapeutics On DCVax Direct At ASCO Excellent presentation and read! Thank you, Smith.
- ADH on Washington Post Calls For An Investigation Into Hedge Fund Trading And Adam Feuerstein's Blogging Their Shorting Afrezza (Mankind Product) too; a...
- kdII on Discovery Laboratories: Surfaxin Launch Is Slow; Aerosurf Outlook Is Key To The Stock Smithonstocks, you were right on about your Pha...
- Smith On Stocks on Neuralstem: Initial Take On Top Line Results Of Phase 2 ALS Trial Of NSI-566 Neural Stem Cells Cytokinetics is one of my recommended stocks. N...
- ceristeare on Neuralstem: Initial Take On Top Line Results Of Phase 2 ALS Trial Of NSI-566 Neural Stem Cells I will start a CUR position once the dust settles.
- Northwest Biotherapeutics' DC Vax Cancer Vaccine May Be A Game Changer In Cancer Therapy ( Comments)
- If You're Going To San Francisco ( Comments)
- Neuralstem: Initial Take On Top Line Results Of Phase 2 ALS Trial Of NSI-566 Neural Stem Cells ( Comments)
- My Dialogue With Adam Feuerstein On Northwest Biotherapeutics ( Comments)
- Northwest Biotherapeutics (NWBO, $6.06, Buy): Comments On First Interim Look At DCVax-L Trial And Recent Weakness In The Stock ( Comments)